Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
Wimbury D, Muto M, Bhachu JS, Scionti K, Brown J, Molyneux K, Seikrit C, Maixnerová D, Pérez-Alós L, Garred P, Floege J, Tesař V, Fellstrom B, Coppo R, Barratt J.
Wimbury D, et al. Among authors: maixnerova d.
Kidney Int. 2024 Feb;105(2):381-388. doi: 10.1016/j.kint.2023.11.003. Epub 2023 Nov 25.
Kidney Int. 2024.
PMID: 38008160
Free article.
No abstract available.